Amarin (NASDAQ:AMRN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $32.37 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Amarin Stock Performance
Shares of AMRN opened at $0.51 on Wednesday. The stock has a 50-day simple moving average of $0.55 and a 200-day simple moving average of $0.56. The stock has a market capitalization of $209.48 million, a PE ratio of -5.67 and a beta of 1.83. Amarin has a 1 year low of $0.43 and a 1 year high of $1.11.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
- Five stocks we like better than Amarin
- Comparing and Trading High PE Ratio Stocks
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What is the S&P 500 and How It is Distinct from Other Indexes
- Tesla Stock: Finding a Bottom May Take Time
- Stock Market Sectors: What Are They and How Many Are There?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
